INDP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Indaptus Therapeutics Insider Trading History Chart

Indaptus Therapeutics Share Price & Price History

^$0.94

▲ +0.048 (5.39%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Indaptus Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2023	Glen R Anderson	Major Shareholder	Buy	23,934	$2.34	$56,005.56	1,190,400
8/10/2023	Glen R Anderson	Major Shareholder	Buy	44,354	$1.94	$86,046.76	1,131,402
12/1/2022	Boyan Vesselinov Litchev	Insider	Buy	500	$1.87	$935.00	1,150
11/22/2022	Boyan Vesselinov Litchev	Insider	Buy	500	$1.83	$915.00	650
11/21/2022	Jeffrey A. Meckler	CEO	Buy	9,600	$1.90	$18,240.00	75,374
11/18/2022	Jeffrey A. Meckler	CEO	Buy	400	$1.76	$704.00	65,774
9/8/2022	Jeffrey A. Meckler	CEO	Buy	10,308	$2.80	$28,862.40	65,374
9/7/2022	Walt Addison Linscott	Insider	Buy	150	$2.62	$393.00	150
6/6/2022	Jeffrey A. Meckler	CEO	Buy	19,727	$2.63	$51,882.01	45,374
3/2/2022	Boyan Vesselinov Litchev	Insider	Buy	50	$4.09	$204.50	150
1/31/2022	Boyan Vesselinov Litchev	Insider	Buy	100	$4.65	$465.00	100
1/31/2022	Michael James Newman	Director	Sell	5,870	$5.00	$29,350.00

Vladimir Lenin was right…

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

SEC Filings (Institutional Ownership Changes) for Indaptus Therapeutics (NASDAQ:INDP)

7.06% of Indaptus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Indaptus Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	14,232	$32K	0.0%	N/A	0.167%
11/9/2023	Investment House LLC	102,849	$0.28M	0.0%	-5.0%	1.224%
8/25/2023	Strategy Asset Managers LLC	45,336	$87K	0.0%	-18.1%	0.540%
8/8/2023	Investment House LLC	108,282	$0.21M	0.0%	+13.2%	1.289%
10/11/2022	Strategy Asset Managers LLC	55,336	$0.12M	0.0%	N/A	0.670%
7/22/2022	Stratos Wealth Partners LTD.	26,832	$70K	0.0%	-97.7%	0.325%
4/26/2022	Stratos Wealth Partners LTD.	1,188,356	$4.75M	0.1%	-14.4%	14.389%
2/9/2022	Investment House LLC	95,629	$0.55M	0.0%	+272.8%	1.167%
1/14/2022	Stratos Wealth Partners LTD.	1,388,356	$7.91M	0.2%	N/A	16.952%
11/15/2021	Marshall Wace LLP	12,780	$100K	0.0%	N/A	0.236%
10/25/2021	Harel Insurance Investments & Financial Services Ltd.	2,958	$25K	0.0%	N/A	0.055%

Data available starting January 2016

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Today's Range

Now: $0.94

$0.89

$0.95

50 Day Range

MA: $1.16

$0.89

$1.91

52 Week Range

Now: $0.94

$0.84

$3.10

Volume

23,784 shs

Average Volume

59,681 shs

Market Capitalization

$9.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Who are the company insiders with the largest holdings of Indaptus Therapeutics?: Indaptus Therapeutics' top insider shareholders include:
Glen R Anderson (Major Shareholder)
Learn More about top insider investors at Indaptus Therapeutics.